Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Spencer, T. J. Articles by Fischman, A. J. Search for Related Content PubMed Citation Articles by Spencer, T. J. Articles by Fischman, A. J. Cannabis Other Somatic Therapy PET Related Article

PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate

OBJECTIVE: The abuse potential of methylphenidate has been related to the drug’s capacity to produce a rapid onset of blockade of the presynaptic dopamine transporter in the brain. An oral once-a-day osmotic controlled-release formulation of methylphenidate produces a more gradual rise in plasma methylphenidate concentration, compared with immediate-release methylphenidate. The authors hypothesized that osmotic-release methylphenidate would also produce a slower onset of blockade of the presynaptic dopamine transporter and would be associated with a lower risk for detection and likeability, compared to immediate-release methylphenidate. METHOD: Twelve healthy adults were randomly assigned to receive single doses of immediate-release methylphenidate or osmotic-release methylphenidate. Doses predicted to produce equivalent maximum concentration (C_max) values were selected (40 mg of immediate-release methylphenidate and 90 mg of osmotic-release methylphenidate). Plasma d-methylphenidate levels and responses to detection/likeability questionnaire items were obtained hourly for 10 hours after administration of methylphenidate on two separate occasions for each subject. Dopamine transporter receptor occupancies were measured at hours 1, 3, 5, and 7 by using a carbon-11-labeled imaging agent (Altropane) and positron emission tomography. RESULTS: Despite similar C_max values for both formulations, osmotic-release methylphenidate was associated with a longer time to maximum concentration, longer time to maximum CNS dopamine transporter occupancy, and no detection/likeability, compared with immediate-release methylphenidate. CONCLUSIONS: The findings suggest that the abuse potential of oral methylphenidate is strongly influenced by the rate of delivery and not solely by the magnitude of plasma concentration or brain transporter occupancy. These results advance understanding of the underlying central effects of methylphenidate in humans and identify a potentially less abusable methylphenidate formulation.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A44. [Full Text] [PDF]

This article has been cited by other articles:

				S. H. Kollins ADHD, Substance Use Disorders, and Psychostimulant Treatment: Current Literature and Treatment Guidelines J Atten Disord, September 1, 2008; 12(2): 115 - 125. [Abstract] [PDF]

				G. Bush, T. J. Spencer, J. Holmes, L. M. Shin, E. M. Valera, L. J. Seidman, N. Makris, C. Surman, M. Aleardi, E. Mick, et al. Functional Magnetic Resonance Imaging of Methylphenidate and Placebo in Attention-Deficit/Hyperactivity Disorder During the Multi-Source Interference Task Arch Gen Psychiatry, January 1, 2008; 65(1): 102 - 114. [Abstract] [Full Text] [PDF]

				D. A. Parasrampuria, K. A. Schoedel, R. Schuller, J. Gu, P. Ciccone, S. A. Silber, and E. M. Sellers Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans J. Clin. Pharmacol., December 1, 2007; 47(12): 1476 - 1488. [Abstract] [Full Text] [PDF]

				R. L. Ehman, W. R. Hendee, M. J. Welch, N. R. Dunnick, L. B. Bresolin, R. L. Arenson, S. Baum, H. Hricak, and J. H. Thrall Blueprint for Imaging in Biomedical Research Radiology, July 1, 2007; 244(1): 12 - 27. [Full Text] [PDF]

				T. E. Wilens Attention Deficit Hyperactivity Disorder and Substance Use Disorders Am J Psychiatry, December 1, 2006; 163(12): 2059 - 2063. [Full Text] [PDF]

				B. K. Madras, Z. Xie, Z. Lin, A. Jassen, H. Panas, L. Lynch, R. Johnson, E. Livni, T. J. Spencer, A. A. Bonab, et al. Modafinil Occupies Dopamine and Norepinephrine Transporters in Vivo and Modulates the Transporters and Trace Amine Activity in Vitro J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 561 - 569. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us